1. < Home

phase 3

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials

Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki[...]

By afschroeder • August 7, 2026
Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]

By sjmartinez • May 18, 2025
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli[...]

By sjmartinez • July 1, 2024
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon[...]

By sjmartinez • November 28, 2023
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon[...]

By sjmartinez • August 20, 2023